Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2019-12-23 Merger & Acquisition
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
S-4
Merger & Acquisition Classification · 100% confidence The document is a Form S-4 registration statement filed with the U.S. Securities and Exchange Commission. It relates to a proposed merger between Organovo Holdings, Inc. and Tarveda Therapeutics, Inc. The text includes detailed information about the merger agreement, stockholder meetings, voting proposals, and the issuance of shares in connection with the merger. Form S-4 is specifically used for securities registration in connection with mergers and acquisitions. The document is not a proxy statement alone, nor is it a simple announcement or a financial report. It is a comprehensive merger-related filing that includes registration of securities and merger details. Therefore, the most appropriate classification is 'Merger & Acquisition' (MA).
2019-12-23 English
8-K
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 13, 2019, by Organovo Holdings, Inc. It details the entry into a material definitive agreement, specifically an Agreement and Plan of Merger with Tarveda Therapeutics, Inc. The text includes detailed descriptions of the merger terms, stockholder approvals required, support agreements, lock-up agreements, and other merger-related information. It also references the filing of a Form S-4 proxy statement/prospectus related to the merger. The document is not a full annual or quarterly report, nor is it an earnings release or audit report. It is a current report disclosing a significant corporate event, namely a merger agreement. This fits the category of M&A Activity filings, which cover announcements and documents related to merger proposals or takeover bids. The document length is substantial (15,000 characters), and it contains detailed substantive information about the merger, not just an announcement or a brief summary. Therefore, the appropriate classification is M&A Activity (Code: TAR).
2019-12-16 English
425 Filing
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 13, 2019, by Organovo Holdings, Inc. It announces the entry into a material definitive agreement, specifically an Agreement and Plan of Merger with Tarveda Therapeutics, Inc. The text details the terms of the merger, stockholder approvals required, changes in board composition, and other merger-related arrangements. It also references support agreements, lock-up agreements, and the filing of a Form S-4 proxy statement related to the merger. The document is a current report announcing a merger transaction and related corporate actions, which fits the definition of M&A Activity filings. It is not a full merger proxy statement or tender offer filing (which would be under MA), but rather an announcement of the merger agreement and related details. Therefore, the appropriate classification is M&A Activity (TAR).
2019-12-16 English
FORM 4 SUBMISSION
Director's Dealing
2019-11-19 English
FORM 4 SUBMISSION
Director's Dealing
2019-11-19 English
FORM 4 SUBMISSION
Director's Dealing
2019-11-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.